Platt R, Ehrlich S L, Afarian J, O'Brien T F, Pennington J E, Kass E H
Antimicrob Agents Chemother. 1981 Sep;20(3):351-5. doi: 10.1128/AAC.20.3.351.
Thirty patients infected predominantly by Serratia marcescens and Pseudomonas aeruginosa were treated in an open trial with moxalactam, a broad-spectrum beta-lactam antibiotic. Twenty-three (76%) had a satisfactory microbiological or clinical response. Among 25 patients for whom serum inhibitory concentrations were measured, those with favorable microbiological responses had significantly higher values than those with poor responses (reciprocal geometric mean concentrations, 49 versus 4.9; P less than 0.01). A serum inhibitory concentration of greater than 1:8 correlated significantly with a favorable outcome (17 of 18 versus 2 of 7 responses; P less than 0.01). Although the overall clinical efficacy of moxalactam was good, resistant organisms of species identical to those of the original infecting isolates were recovered during therapy in seven cases, including five caused by Pseudomonas organisms and two caused by Serratia organisms.
30名主要感染粘质沙雷氏菌和铜绿假单胞菌的患者接受了一项开放性试验，使用广谱β-内酰胺抗生素莫拉西林进行治疗。23名（76%）患者有满意的微生物学或临床反应。在25名测量了血清抑菌浓度的患者中，微生物学反应良好的患者血清抑菌浓度值显著高于反应不佳的患者（倒数几何平均浓度分别为49和4.9；P<0.01）。血清抑菌浓度大于1:8与良好预后显著相关（18例中有17例反应良好，7例中有2例反应良好；P<0.01）。虽然莫拉西林的总体临床疗效良好，但在治疗期间，7例患者分离出与最初感染菌株相同的耐药菌，其中5例由假单胞菌引起，2例由沙雷氏菌引起。
